Iohexol with 120kVp

Phase 3Small molecule

JJung Im Jung

Iohexol with 120kVp is one of 14 small molecule programs targeting Concentration. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConcentrationRecruiting

ConcentrationPhase 3

Recruiting

Competition

Competitive Landscape

17 competitors in Concentration

#DrugCompanyPhaseTrials

Vibativ

AApotex Inc.

Approved

1 2

Wilate

Octapharma

Phase 3

1 3

Iohexol with 120kVp

JJung Im Jung

Phase 3

1 4

Xyrem

Jazz Pharmaceuticals

Preclinical

1 5

Inhaled Nitric Oxide

LLee's Pharmaceutical Limited

Phase 1

1 6

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

3 7

Vfend

PPrism Pharmaceuticals

Preclinical

3 8

Zibotentan/dapagliflozin

AstraZeneca

Phase 1

1 9

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

1 10

Blood Redrawal

CCentre Hospitalier Universitaire, Amiens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Concentration1 trial

Chest CT Using Low-concentration Iodine Contrast Media

Recruiting·JJung Im Jung·Phase 4·NCT05967117·370 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iohexol with 120kVp. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iohexol with 120kVp compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iohexol with 120kVp. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jung Im Jung company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJung Im Jung

Iohexol with 120kVp

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Concentration1 trial

References

Drug Info

Quick Facts

Related News